Lactulose Marel (Lactulose)

Lactulose is a synthetic sugar that reaches the colon unchanged, where gut bacteria split it into short‑chain fatty acids. These acids increase the osmotic load, drawing water into the intestinal lumen and softening stool. The resulting acidic environment converts ammonia to ammonium, which is less readily absorbed, thereby reducing systemic ammonia levels.

The dose of Lactulose Marel is individualized by the prescribing clinician based on the patient’s condition, age, renal function and response. Typical regimens for constipation or hepatic encephalopathy are titrated to achieve the desired clinical effect, and the prescriber determines the exact amount and frequency.

Safety data for lactulose during pregnancy and lactation are limited. It is generally categorized as low risk because it is minimally absorbed, but the decision to use it should be based on a careful risk‑benefit assessment by the treating physician. Breastfeeding mothers should consult their healthcare provider before starting therapy.

To place an order, submit an enquiry on the Lactulose Marel product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lactulose is an osmotic laxative, differing from stimulant laxatives that act on intestinal nerves. Its non‑systemic action and ability to lower ammonia make it uniquely suitable for hepatic encephalopathy, a benefit not shared by most other laxatives. For simple constipation, it may be slower to act but offers a gentler, water‑based mechanism.

Lactulose Marel should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed when not in use and store away from sources of heat. No refrigeration is required for this oral formulation.

Lactulose Marel is taken orally, usually as a liquid or syrup that can be measured with a calibrated device and swallowed directly or mixed with a small amount of water or juice. The exact administration technique, including timing relative to meals, is determined by the prescribing clinician.

Serious risks include severe electrolyte disturbances such as hyponatremia or hypernatremia, marked dehydration, and rare allergic reactions that may present as rash, urticaria or anaphylaxis. Patients should be monitored for signs of these conditions, especially during high‑dose or prolonged therapy.

Lactulose Marel is contraindicated in individuals with known hypersensitivity to lactulose or any component of the formulation. Caution is advised for patients with severe renal impairment, uncontrolled diabetes, or those who require strict fluid restriction, as the osmotic effect may exacerbate existing conditions.